Epigenetic inactivation of RUNX3 in colorectal cancer

Eung Jin Shin; Han Jo Kim; Myoung Won Son; Tae Sung Ahn; Hyun Yong Lee; Dae Ro Lim; Sang Byung Bae; Seob Jeon; Hyungjoo Kim; Dongjun Jeong; Moon Soo Lee; Dong Sun Kim; Jeong Se Noh; Moo Jun Baek

doi:10.4174/astr.2018.94.1.19

Epigenetic inactivation of RUNX3 in colorectal cancer

Eung Jin Shin, Han Jo Kim, Myoung Won Son, Tae Sung Ahn, Hyun Yong Lee, Dae Ro Lim, Sang Byung Bae, Seob Jeon, Hyungjoo Kim, Dongjun Jeong, Moon Soo Lee, Dong Sun Kim, Jeong Se Noh, Moo Jun Baek

Department of Medicine

Soonchunhyang University

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Purpose: Emerging evidence indicates that runt-related transcription factor 3 (RUNX3) is an important tumor suppressor gene in several cancer types, including colorectal cancer (CRC). However, the clinical significance of RUNX3 inactivation in CRC remains unclear. The aim of this study was to examine the correlation between clinicopathologic factors and RUNX3 hypermethylation/expression in CRC. Methods: Sixty-two CRC patients who were treated at the Soonchunhyang University College of Medicine were recruited in this study. The hypermethylation of CpG islands in the RUNX3 promoter and the expression of RUNX3 mRNA were identified by methylation-specific polymerase chain reaction (PCR) and reverse transcriptase-PCR, respectively. The expression of RUNX3 was determined by immunohistochemical staining. Results: Of the 62 CRC tissue samples, 20 (32.3%) presented hypermethylated RUNX3 promoters. Aberrant RUNX3 hypermethylation was found to be associated with vascular (P = 0.006) and lymphatic (P = 0.002) invasion. Hypermethylation of RUNX3 was associated with poor survival outcomes (P = 0.038). However, expression of RUNX3 was not a prognostic factor (P = 0.363). Conclusion: Hypermethylation of RUNX3 may be a predictor of a poor prognosis in CRC.

Original language	English
Pages (from-to)	19-25
Number of pages	7
Journal	Annals of Surgical Treatment and Research
Volume	94
Issue number	1
DOIs	https://doi.org/10.4174/astr.2018.94.1.19
State	Published - Jan 2018

Keywords

Colorectal neoplasms
Immunohistochemistry
Methylation
Prognosis
RUNX3 protein

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4174/astr.2018.94.1.19

Cite this

@article{7eaf0c8e68fa45499f66a62a3d68226a,

title = "Epigenetic inactivation of RUNX3 in colorectal cancer",

abstract = "Purpose: Emerging evidence indicates that runt-related transcription factor 3 (RUNX3) is an important tumor suppressor gene in several cancer types, including colorectal cancer (CRC). However, the clinical significance of RUNX3 inactivation in CRC remains unclear. The aim of this study was to examine the correlation between clinicopathologic factors and RUNX3 hypermethylation/expression in CRC. Methods: Sixty-two CRC patients who were treated at the Soonchunhyang University College of Medicine were recruited in this study. The hypermethylation of CpG islands in the RUNX3 promoter and the expression of RUNX3 mRNA were identified by methylation-specific polymerase chain reaction (PCR) and reverse transcriptase-PCR, respectively. The expression of RUNX3 was determined by immunohistochemical staining. Results: Of the 62 CRC tissue samples, 20 (32.3%) presented hypermethylated RUNX3 promoters. Aberrant RUNX3 hypermethylation was found to be associated with vascular (P = 0.006) and lymphatic (P = 0.002) invasion. Hypermethylation of RUNX3 was associated with poor survival outcomes (P = 0.038). However, expression of RUNX3 was not a prognostic factor (P = 0.363). Conclusion: Hypermethylation of RUNX3 may be a predictor of a poor prognosis in CRC.",

keywords = "Colorectal neoplasms, Immunohistochemistry, Methylation, Prognosis, RUNX3 protein",

author = "Shin, {Eung Jin} and Kim, {Han Jo} and Son, {Myoung Won} and Ahn, {Tae Sung} and Lee, {Hyun Yong} and Lim, {Dae Ro} and Bae, {Sang Byung} and Seob Jeon and Hyungjoo Kim and Dongjun Jeong and Lee, {Moon Soo} and Kim, {Dong Sun} and Noh, {Jeong Se} and Baek, {Moo Jun}",

note = "Publisher Copyright: Copyright {\textcopyright} 2018, the Korean Surgical Society.",

year = "2018",

month = jan,

doi = "10.4174/astr.2018.94.1.19",

language = "English",

volume = "94",

pages = "19--25",

journal = "Annals of Surgical Treatment and Research",

issn = "2288-6575",

publisher = "Korean Surgical Society",

number = "1",

}

TY - JOUR

T1 - Epigenetic inactivation of RUNX3 in colorectal cancer

AU - Shin, Eung Jin

AU - Kim, Han Jo

AU - Son, Myoung Won

AU - Ahn, Tae Sung

AU - Lee, Hyun Yong

AU - Lim, Dae Ro

AU - Bae, Sang Byung

AU - Jeon, Seob

AU - Kim, Hyungjoo

AU - Jeong, Dongjun

AU - Lee, Moon Soo

AU - Kim, Dong Sun

AU - Noh, Jeong Se

AU - Baek, Moo Jun

PY - 2018/1

Y1 - 2018/1

N2 - Purpose: Emerging evidence indicates that runt-related transcription factor 3 (RUNX3) is an important tumor suppressor gene in several cancer types, including colorectal cancer (CRC). However, the clinical significance of RUNX3 inactivation in CRC remains unclear. The aim of this study was to examine the correlation between clinicopathologic factors and RUNX3 hypermethylation/expression in CRC. Methods: Sixty-two CRC patients who were treated at the Soonchunhyang University College of Medicine were recruited in this study. The hypermethylation of CpG islands in the RUNX3 promoter and the expression of RUNX3 mRNA were identified by methylation-specific polymerase chain reaction (PCR) and reverse transcriptase-PCR, respectively. The expression of RUNX3 was determined by immunohistochemical staining. Results: Of the 62 CRC tissue samples, 20 (32.3%) presented hypermethylated RUNX3 promoters. Aberrant RUNX3 hypermethylation was found to be associated with vascular (P = 0.006) and lymphatic (P = 0.002) invasion. Hypermethylation of RUNX3 was associated with poor survival outcomes (P = 0.038). However, expression of RUNX3 was not a prognostic factor (P = 0.363). Conclusion: Hypermethylation of RUNX3 may be a predictor of a poor prognosis in CRC.

AB - Purpose: Emerging evidence indicates that runt-related transcription factor 3 (RUNX3) is an important tumor suppressor gene in several cancer types, including colorectal cancer (CRC). However, the clinical significance of RUNX3 inactivation in CRC remains unclear. The aim of this study was to examine the correlation between clinicopathologic factors and RUNX3 hypermethylation/expression in CRC. Methods: Sixty-two CRC patients who were treated at the Soonchunhyang University College of Medicine were recruited in this study. The hypermethylation of CpG islands in the RUNX3 promoter and the expression of RUNX3 mRNA were identified by methylation-specific polymerase chain reaction (PCR) and reverse transcriptase-PCR, respectively. The expression of RUNX3 was determined by immunohistochemical staining. Results: Of the 62 CRC tissue samples, 20 (32.3%) presented hypermethylated RUNX3 promoters. Aberrant RUNX3 hypermethylation was found to be associated with vascular (P = 0.006) and lymphatic (P = 0.002) invasion. Hypermethylation of RUNX3 was associated with poor survival outcomes (P = 0.038). However, expression of RUNX3 was not a prognostic factor (P = 0.363). Conclusion: Hypermethylation of RUNX3 may be a predictor of a poor prognosis in CRC.

KW - Colorectal neoplasms

KW - Immunohistochemistry

KW - Methylation

KW - Prognosis

KW - RUNX3 protein

UR - http://www.scopus.com/inward/record.url?scp=85040715692&partnerID=8YFLogxK

U2 - 10.4174/astr.2018.94.1.19

DO - 10.4174/astr.2018.94.1.19

M3 - Article

AN - SCOPUS:85040715692

SN - 2288-6575

VL - 94

SP - 19

EP - 25

JO - Annals of Surgical Treatment and Research

JF - Annals of Surgical Treatment and Research

IS - 1

ER -

Epigenetic inactivation of RUNX3 in colorectal cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this